



Global Monthly Update

November 2020



Virtual Grower Trainings to Support Produce Safety Culture in Latin America

FDA's Latin America office (LAO), in conjunction with the Inter-American Institute for Cooperation on Agriculture (IICA) and the Joint Institute for Food Safety and Applied Nutrition (JIFSAN), has developed and implemented a virtual Grower Training pilot program that took advantage of a shift in policy by the Produce Safety Alliance (PSA), which in March of 2020 expanded its traditional in-person only training curriculum to online during the COVID-19 pandemic.



FDA's Produce Safety Rule requires that at least one individual from most farms receive certification for produce safety training using a curriculum deemed adequate by the FDA. To date, only one curriculum exists, developed by Cornell University through the Produce Safety Alliance.

LAO's virtual Grower Training pilot conducted 16 courses in Mexico, Honduras, Chile and the Dominican Republic from May-Sept. 2020, certifying 222 growers as being in compliance with the Produce Safety Rule training requirement. Additionally, FDA, IICA, and JIFSAN were able to

gain valuable knowledge about the effectiveness of online training which will inform the design and execution of similar learning programs in the future.

The pilot's initial successes led to the development of a "Phase Two," which will consist of eight additional trainings for growers in hard-to-reach or high-risk produce growing regions of Mexico and Honduras. JIFSAN has contracted with a PSA expert to develop teams of PSA Trainers and Lead Trainers in Mexico and Honduras to recruit growers and co-teach portions of the PSA Grower's curriculum in those locations. Growers are enthusiastic about this training opportunity and the PSA expert has reported full rosters for all courses.

The objective of the training effort is to reach Latin American farmers, increase compliance with FDA's Produce Safety Rule, and enhance the safety of produce consumed in the United States. Evidence shows training on safe agricultural practices can improve produce safety. Approximately 40% of the fruits and vegetables consumed in the U.S. are of foreign origin and more than 80% of these imports originate in Latin America, which means that training growers in this region is a high-value investment towards ensuring the safety of food imported to the U.S.

LAO believes its work on Grower Training has helped to build and strengthen its relationships with significant partners in produce-rich countries, which in turn will enhance opportunities for collaboration and food safety culture achievement in the future.

For example, in Mexico, LAO has coordinated with major export associations for help in both logistic and training support, including the cilantro industry's UNACOMEX in Puebla, and the Association of Berry Growers (ANEBERRIES).

In addition to providing the standard curriculum, LAO used the virtual trainings as an opportunity to convey additional information on the Food Safety Partnership that FDA signed with Mexico's National Service of Agro-Alimentary Health, Safety and Quality (SENASICA, for its initials in Spanish) and the Federal Commission for the Protection from Sanitary Risks (COFEPRIS, for its initials in Spanish) on Sept. 29. Personnel from SENASICA were invited to the training to present information about Mexico's voluntary System for Risk and Contamination Reduction Program (SRRC, for its initials in Spanish), an initiative of the Mexican government to strengthen the safety of their growers' agricultural practices while personnel from LAO discussed the FDA's import requirements, 'what to expect' during an FDA inspection, and the parallel features of Mexico's SRRC and the FDA's Produce Safety Rule.

As a result of the success of these courses, continued demand from growers, and the pandemic's ongoing limitations for in-person events, LAO, IAS, and JIFSAN are planning additional virtual trainings in 2021.

FDA and Homeland Security Sign MOU to Stop Harmful Products Through International Mail

Announced on Oct. 30, leadership from the U.S. Food and Drug Administration and offices within the Department of Homeland Security — the U.S. Customs and Border Protection (CBP), and the U.S. Immigration and Customs Enforcement, Homeland Security Investigations (ICE-HSI) — signed a Memorandum of Understanding (MOU) to stop products that pose a threat to public health and attempt to enter the U.S. through our International Mail Facilities (IMFs).



The MOU will maximize inspection and detection capabilities in order to prevent this illegal activity. "The collaborative efforts we've announced will enable more resourceful, effective, and efficient oversight to prevent illegal and potentially harmful products from entering the United States," FDA Commissioner Stephen M. Hahn, M.D., noted.

As a core part of this collaborative effort, CBP and ICE-HSI will continue to partner with the FDA in joint operations at the IMFs to target illicit opioids, including fentanyl and other unapproved or unlawful drugs; medical devices; and dietary supplements regulated under the Federal Food, Drug, and Cosmetic Act. The partnership is also critical in the FDA's continuing efforts to intercept fraudulent, counterfeit, or illegitimate COVID-19 products that may pose risks to public health.

The FDA and CBP signed a letter of intent in April 2019, to maximize inspection and detection capabilities at the IMFs. As outlined in the letter of intent and in the recently signed MOU, the FDA, CBP, and ICE-HSI will expand the types of information and how that information is shared among the agencies to quickly and effectively identify trends in incoming violative packages.

Both general and specific data points will be shared, which can be used to target impending product entries and to inform future enforcement strategies and coordinated operations. An additional focus of this effort will be coordinating the shared space and increased scientific presence at high-volume IMF locations, helping to facilitate and support real-time entry decisions, and increased data sharing.

As of the end of Oct. 2020, the FDA has screened approximately 27,500 mail parcels, containing almost 43,000 FDA-regulated products — already more than the agency did in all of 2019. Of these products, more than 34,000 were refused admission and more than 24,000 were violative drug products that have been destroyed using FDA's administrative destruction authority, a process made more efficient by the 2018 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. Enforcement is managed by the FDA's Office of Regulatory Affairs, Office of Enforcement and Import Operations, for nine IMFs at the ports of Los Angeles, San Francisco, Honolulu, Chicago, New Jersey, New York, Miami, Puerto Rico, and the Virgin Islands.

FDA Publishes List of Essential Medicines

Responding to a recent Executive Order (EO), the FDA has identified a list of essential medicines, medical countermeasures and critical inputs that are medically necessary to have available at all times, in an amount adequate to serve patient needs and in the appropriate dosage forms.



The EO was issued on Aug. 6 to ensure the American public is protected against outbreaks of emerging infectious diseases, such as COVID-19, as well as chemical, biological, radiological, and nuclear threats. To accomplish this goal, the EO seeks to minimize potential shortages of these products and reduce U.S. dependence on foreign manufacturers by ensuring sufficient and reliable, long-term domestic production of these products.

The FDA was given a 90-day deadline to respond to the EO and worked in consultation with other federal partners to identify a list of 227 drug and biological product essential medicines and medical countermeasures. Additionally, 96 device medical countermeasures were identified, including diagnostic testing kits and supplies for rapid test development and processing, personal protective equipment, active vital sign monitoring devices, devices for vaccine delivery, and devices for management of acute illnesses, such as ventilators, among others.

Generally, the essential medicines identified by FDA are those that are most needed for patients in U.S. acute care medical facilities, which specialize in short-term treatment for severe injuries or illnesses, and urgent medical conditions. The medical countermeasures identified are FDA-regulated products (biologics, drugs, devices) that meet the definition of a "medical countermeasure" provided in the executive order and that FDA anticipates will be needed to respond to future pandemics, epidemics, and chemical, biological, and radiological/nuclear threats.

For the greatest public health impact, the list concentrates on those medicines that are medically necessary to have in adequate supply for use by the widest populations. The critical inputs identified included related active pharmaceutical ingredients, as well as ingredients or components that possess unique attributes essential in assessing the safety and effectiveness of such products.



The medicines and devices on the list are up for public comment under docket FDA-2020-N-2123-0001 for feedback on any additions or removals, inclusion criteria, and how often the list should be updated.

The EO also directed the FDA to coordinate with its federal partners on strategies for acquiring the products on the list, accelerating domestic manufacturing, and identifying and addressing supply chain vulnerabilities. The FDA believes that the adoption of innovative technologies, such as advanced manufacturing techniques, could enable U.S.-based pharmaceutical

manufacturing to bolster its competitiveness with foreign countries and help ensure a stable supply of drugs critical to the health of U.S. patients.

<https://www.whitehouse.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-countermeasures-critical-inputs-made-united-states/>

<https://www.fda.gov/news-events/congressional-testimony/safeguarding-pharmaceutical-supply-chains-global-economy-10302019>

<https://www.fda.gov/news-events/press-announcements/fda-publishes-list-essential-medicines-medical-countermeasures-critical-inputs-required-executive>

Transitions

Welcome



Gabrielle Lamourelle has been selected for a 120-day detail as director of the Office of Global Diplomacy and Partnerships (OGDP) in the Office of Global Policy and Strategy (OGPS). She had been serving as the deputy director for multilateral relations within the HHS Office of Global Affairs (OGA) since 2016 where she led and contributed to U.S. negotiations at the World Health Assembly, the United Nations General Assembly, and other key forums on health matters; managed special projects, such as drafting the HHS Global Strategy; and served as OGA's focal point on noncommunicable diseases (NCDs) and injuries.

Lamourelle has over 18 years of global health experience in the public sector and non-governmental organizations, with a focus on access to health technologies and services in low-resource settings. Her work prior to federal service included piloting human papillomavirus vaccines in Uganda; supporting new community health worker programs and alternate primary care models in India; and policy research and advocacy on development of and access to new HIV prevention technologies.

Lamourelle holds a Master of Public Health in sociomedical sciences with a concentration in global health from the Mailman School of Public Health at Columbia University and a Bachelor of Arts degree in sociology from the University of California at Berkeley.



Heidi Marks has accepted a permanent position on the Communications Team of the Office of Global Diplomacy and Partnerships as a writer-editor. She served in this capacity on detail to OGPS beginning July 20 from the Office of Regulatory Affairs (ORA), where she worked over 29 years as a research chemist, regulatory chemist, and both a domestic and import compliance officer; and was detailed as a writer-editor for ORA Strategic Communications.

Louati Discusses Biosimilars During Conference

Claudia Louati, a policy advisor in the FDA's [Europe Office](#) (EO), discussed the U.S. regulatory framework for biosimilars and interchangeable biological products during a one-hour session at the RAPS Euro Convergence 2020 virtual meeting on Oct. 30.

The Regulatory Affairs Professionals Society is the largest global organization those involved with the regulation of healthcare and related products—including medical devices, pharmaceuticals, biologics and nutritional products. The meeting was initially scheduled to take place in Brussels in May but was postponed and then converted to a virtual format due to the pandemic. Louati worked closely with colleagues from the Center for Drug Evaluation and Research to develop the presentation and gather updates on the latest developments.



FDA [requires](#) that biosimilar and interchangeable biological products meet the agency's rigorous approval standards. Congress created an abbreviated licensure through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009. This pathway was established to provide more treatment options, increase access to lifesaving medications, and potentially lower health care costs through competition.

Louati's session explored the regulatory challenges of biosimilars and aimed to increase awareness and knowledge of this pathway. Other panelists

included Irene Milobratovic and Gabriela Marton of Arriello; and Jennifer Neff, Ph.D., of Bess AG.

DIA China Annual Meeting Supports Priorities

One of the priorities of the OGPS [China Office](#) (CNO) is to engage with regulatory authorities, industry, academia, multilateral organizations, non-governmental organizations, and other relevant institutions to increase the FDA's understanding of China's regulatory framework and processes and share information about FDA science-based regulations and requirements.

The Drug Information Association's 12th China Annual Meeting in Suzhou offered one opportunity for CNO to participate in such information sharing. More than 3,000 professionals from different continents and regions participated in the Oct. 27-30 meeting to discuss current issues related to healthcare products, technologies and services.



CNO staff co-organized two morning sessions: *Global Practice of Biological Medicine GMP Supervision and Implementation* along with Yeehong Business School and Shenyang Pharmaceutical University where CNO International Program and Policy Analyst Lane Christensen, Ph.D., was the moderator.

Inspection of Licensed Biological Therapeutic Drug Products: An FDA Perspective was delivered by Supervisory Consumer Safety Officer Marijo Kambere, Ph.D.



CNO Office Director Vanessa Shaw-Dore (center in stripes), Marijo Kambere (center in black), Lane Christensen and Medical Program Coordinator Qian Wang (far right), along with other participants.

At the conclusion of the session, CNO staff met with the Dean of Yeehong Business School and other Yeehong leadership to introduce CNO Country Director [Vanessa Shaw-Dore](#) and to discuss priorities and areas for continued cooperation. They acknowledged previous successes and committed to continually work together on priority issues.

Conference Brings Global Experts Together

Education and outreach on food safety is also a China Office responsibility. Four CNO officials, Country Director Vanessa Shaw-Dore; Deputy Country Director Latasha Robinson; Supervisory Consumer Safety Officer Jennifer Mathern; and Food Program Coordinator Nannan Zhang, participated in the 2020 China International Food Safety & Quality Conference (CIFSQ) in Shanghai, China, on Nov. 4-5.

The conference drew over 900 participants from competent authorities, academia and industry, both in person or virtually, from China and abroad. Robinson was a panelist for a plenary discussion entitled *Role of Biotech and Infotech Innovations in Improving/Ensuring Food Safety and Nutrition*.



(L-R) Latasha Robinson, Vanessa Shaw-Dore, conference participant, and Jennifer Mathern

Other topics discussed by 140 food experts from 20 countries included advances in food supply chain digital technology; global collaboration on food adulteration; changes in international food regulations and audits; anti-microbial resistance research on animal pathogens; the latest developments in testing and analysis methods; new directions in risk communications; and food safety issues during and after COVID-19.



Vanessa Shaw-Dore and Jennifer Mathern with conference participant

Europe Office Fosters Spanish Industry Understanding of Food Import Requirements



On Nov. 19, at the request of the Foreign Agricultural Services (FAS) and the U.S. Embassy in Spain, the FDA Europe Office (EO) presented in a seminar with the Spanish Federation of Food and Drink Industries (FIAB).

EO Director Ritu Nalubola, Ph.D., provided an overview of the FDA's food safety priorities and import requirements for Spanish companies exporting to the U.S. The topics for discussion included the implementation of the [Food Safety Modernization Act](#) (FSMA), the [New Era of Smarter Food Safety](#), and the recent [shellfish equivalence determination](#) enabling resumption of bivalve molluscan shellfish trade, including from Spain.

Emer Cooke Takes Office as Head of EMA



Emer Cooke is the new executive director of the [European Medicines Agency](#) (EMA), the agency responsible for regulating and approving human and animal drugs in the EU. Cooke, who is the first woman to lead the EMA, began her five-year term in November 2020.

Taking the reins in the middle of the pandemic, Cooke assured the public, "My number one priority will be to drive forward EMA's response to the pandemic and the work already ongoing to support the development and approval of safe and effective COVID-19 vaccines and treatments."

Cooke recognizes other challenges to tackle too: antibiotic resistance, supporting new waves of innovation, and making the most of the opportunities provided by the digitalization of medicine

discovery and development. With 30 years of experience in international regulatory affairs, including 18 in leadership roles, Cooke is looking forward to working with the EU and other regulators around the world in a global approach to public health safety.

The EO is also building an internal FDA GDPR stakeholder list, which will be used to send future updates about GDPR. Do you work with European data sets? Has your work been impacted by GDPR? Let the EO know!

If you want to be added to the list or have any questions or concerns about the GDPR, please contact **Heather Messick, International Policy Analyst, Europe Office** Heather.Messick@fda.hhs.gov.

Dear International Colleague

The Dear International Colleague Letter (DICL) is a letter sent via email to a list-serve of about 20,000 subscribers – both DC-based embassies and international stakeholders. The DICL is intended to inform these stakeholders of any FDA announcements that are relevant to an audience with international interests. Here are the most recent DICLs:

[FDA Publishes List of Essential Medicines, Medical Countermeasures, Critical Inputs Required by Executive Order](#)

[Virtual Public Meetings for Proposed Rule](#)

Upcoming events

December 1 [World AIDS Day](#)

December 2 [Traceability Public Meeting](#)

Newsletter Submissions

Have submissions for the newsletter? Please send them to

Rebecca.Newton@fda.hhs.gov.

Please Note

This content is intended for the internal OGPS audience. A separate newsletter, *Global Monthly Update*, can be shared broadly.

Don't Forget

Don't Forget

OGPS maintains a Twitter account. Please follow us @FDA_Global.

Connect with Us

Read thought-provoking pieces covering international topics in [From A Global Perspective](#).

Subscribe

Don't miss out on future Global Monthly Updates or other international news from OGPS. To sign up, click "Manage Subscriptions" below then follow the prompts and select the "International Programs" box.



[Manage Subscriptions](#) | [Unsubscribe All](#) | [Help](#)